ArticleBMC medical research methodology2026
Simulation-based assessment of a Bayesian M-spline survival model with flexible baseline hazard and time-dependent effects.
Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network Meta-Analysis of Survival Outcomes With Non-Proportional Hazards Using Flexible M-Splines.Statistics in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThere is increasing interest in flexible Bayesian models for the analysis of time-to-event data, especially with their use in medical applications such as Health Technology Assessment (HTA). While these Bayesian approaches offer advantages of incorporating prior knowledge and transparently expressing model uncertainty to aid decision-making, they remain underused in practice. A flexible Bayesian model has recently been proposed for use in HTA settings which uses M-splines to model the hazard function, and is implemented in the survextrap R package.
methodsWe conducted a simulation study to assess the statistical performance of the Bayesian survival model implemented in survextrap. We simulate survival outcomes based on control arm data from two oncology clinical trials, and generate treatment arm survival based on different realistic treatment effect scenarios. Statistical performance in modelling a single treatment arm or the difference between treatment arms is compared across a range of flexible models, varying the M-spline specification, smoothing procedure, priors, treatment effect modelling choices and other computational settings.
resultsWe demonstrate good model fit and convergence of complex baseline hazard functions and time-dependent covariate effects across realistic clinical trial scenarios. We show that a sufficiently flexible M-spline, implemented using a weighted random walk prior on the spline coefficients, can provide a smooth fit to the hazard without risk of overfitting, and gives unbiased estimates of restricted mean survival over the trial follow-up with good coverage of the credible intervals. Bayesian model fitting with an efficient Laplace approximation provides unbiased estimation but overestimates posterior variance. In some treatment effect scenarios, the survextrap non-proportional hazards models displayed greater bias than standard frequentist survival modelling tools such as flexsurv and rstpm2.
conclusionsThis work helps inform key considerations to guide model selection and estimation performance when fitting flexible Bayesian models to trial data. These findings help identify appropriate default model settings in the software that should perform well in a broad range of settings, as well as more specific considerations to guide model selection for advanced users. This work further ensures users have greater confidence in the validity of these survival models and their implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.